In focus · trending topic

CYC065

25 stories · following the connections

Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results

By Nasdaq OMXMay 8, 2018, 11:00 AM UTC

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

By Nasdaq OMXApr 17, 2018, 1:00 PM UTC

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

By Nasdaq OMXApr 16, 2018, 11:01 AM UTC

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

By Nasdaq OMXMar 28, 2018, 8:05 PM UTC

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

By Nasdaq OMXMar 21, 2018, 11:00 AM UTC

Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

By Nasdaq OMXMar 15, 2018, 11:01 AM UTC

Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference

By Nasdaq OMXMar 6, 2018, 12:19 PM UTC

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

By Nasdaq OMXFeb 21, 2018, 12:03 PM UTC